close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.170 +0.280 (+4.75%)
Official Closing Price Updated: 8:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
41 42 Next >
News headline image
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin ↗
Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”)... 
Via Benzinga
News headline image
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72 
Via Benzinga
New Research Finds That Individuals Prefer Guide with Personal Psilocybin Experience
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study
Via Investor Brand Network
News headline image
Cybin Acquires DMT Clinical Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
News headline image
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements
Via Investor Brand Network
News headline image
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From June 3, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article
Via Investor Brand Network
News headline image
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
News headline image
Cybin, GH Research Among Top Psychedelic Movers Of Today ↗
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.50% at $0.75 
Via Benzinga
News headline image
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics
Via Investor Brand Network
News headline image
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
News headline image
ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today ↗
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91 
Via Benzinga
Oregon Adopts First Installment of Psilocybin Rules
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From May 31, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 8.54% at $0.36 
Via Benzinga
News headline image
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog ↗
Cybin Inc. (CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics," has submitted an Investigational New Drug (or “IND”) application to the FDA. 
Via Benzinga
How Your Mental Health May Benefit from a Digital Detox
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain
Via Investor Brand Network
News headline image
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin
Via Business Wire
News headline image
Psychedelic Compounds-Based Stocks Continue To Decline ↗
Our index tracks 6 of the largest clinical-stage startups, which have an average market capitalization of $65.5M and an average stock price of $0.69/share. 
Via Talk Markets
VC Executive Shares Insights into Legal Psychedelics Landscape
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From May 26, 2022 ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 21.06% at $0.34 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds
Via Investor Brand Network
News headline image
TripAdvisor, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗
GAINERS: TripAdvisor (NASDAQ:TRIP) shares closed up 6.06% at $23.45 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From May 24, 2022 ↗
GAINERS: LOSERS: Cybin (AMEX:CYBN) shares closed down 9.99% at $0.61 
Via Benzinga
CSIRO to Collaborate with Biotechnology Firms on Psychedelic Research
Via Investor Brand Network
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today